JP2019510810A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019510810A5 JP2019510810A5 JP2018560739A JP2018560739A JP2019510810A5 JP 2019510810 A5 JP2019510810 A5 JP 2019510810A5 JP 2018560739 A JP2018560739 A JP 2018560739A JP 2018560739 A JP2018560739 A JP 2018560739A JP 2019510810 A5 JP2019510810 A5 JP 2019510810A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- compound
- alkyl
- membered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 55
- 150000003839 salts Chemical class 0.000 claims description 22
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- 239000001257 hydrogen Substances 0.000 claims description 16
- 150000002431 hydrogen Chemical class 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 6
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 125000000623 heterocyclic group Chemical group 0.000 claims description 6
- 125000002950 monocyclic group Chemical group 0.000 claims description 5
- 125000000081 (C5-C8) cycloalkenyl group Chemical group 0.000 claims description 4
- 208000035473 Communicable disease Diseases 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 238000011319 anticancer therapy Methods 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 230000000840 anti-viral effect Effects 0.000 claims description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 125000005865 C2-C10alkynyl group Chemical group 0.000 claims description 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 239000003443 antiviral agent Substances 0.000 claims description 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 2
- 125000004104 aryloxy group Chemical group 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 238000002659 cell therapy Methods 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 208000024558 digestive system cancer Diseases 0.000 claims description 2
- 230000002357 endometrial effect Effects 0.000 claims description 2
- 201000010231 gastrointestinal system cancer Diseases 0.000 claims description 2
- 238000009169 immunotherapy Methods 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 230000002611 ovarian Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 229960004854 viral vaccine Drugs 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 description 11
- 238000000034 method Methods 0.000 description 10
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662293219P | 2016-02-09 | 2016-02-09 | |
| US62/293,219 | 2016-02-09 | ||
| US201662362875P | 2016-07-15 | 2016-07-15 | |
| US62/362,875 | 2016-07-15 | ||
| PCT/US2017/017063 WO2017139414A1 (en) | 2016-02-09 | 2017-02-08 | Inhibitor of indoleamine-2,3-dioxygenase (ido) |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019510810A JP2019510810A (ja) | 2019-04-18 |
| JP2019510810A5 true JP2019510810A5 (enExample) | 2020-03-12 |
| JP6979036B2 JP6979036B2 (ja) | 2021-12-08 |
Family
ID=59563504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018560739A Active JP6979036B2 (ja) | 2016-02-09 | 2017-02-08 | インドールアミン−２，３−ジオキシゲナーゼ（ｉｄｏ）阻害剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US10980807B2 (enExample) |
| EP (1) | EP3414224B1 (enExample) |
| JP (1) | JP6979036B2 (enExample) |
| KR (1) | KR102486298B1 (enExample) |
| CN (2) | CN109071423A (enExample) |
| AU (1) | AU2017217536A1 (enExample) |
| BR (1) | BR112018015413A2 (enExample) |
| CA (1) | CA3012133A1 (enExample) |
| MX (1) | MX2018009633A (enExample) |
| RU (1) | RU2018128334A (enExample) |
| WO (1) | WO2017139414A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020502180A (ja) * | 2016-12-20 | 2020-01-23 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | インドールアミン２，３−ジオキシゲナーゼのモジュレーター |
| JP2020506895A (ja) | 2017-01-17 | 2020-03-05 | ボード オブ レジェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System | インドールアミン２，３−ジオキシゲナーゼおよび／またはトリプトファンジオキシゲナーゼの阻害剤として有用な化合物 |
| US20210139467A1 (en) * | 2017-06-28 | 2021-05-13 | Glaxosmithkline Intellectual Property Development Limited | Modulators of indoleamine 2,3-dioxygenase |
| WO2019027855A1 (en) * | 2017-08-02 | 2019-02-07 | Merck Sharp & Dohme Corp. | NOVEL SUBSTITUTED PHENYL COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE (IDO) |
| WO2019042451A1 (zh) * | 2017-09-01 | 2019-03-07 | 南京药捷安康生物科技有限公司 | 氘代的吲哚胺2,3-双加氧酶抑制剂及其应用 |
| US11111232B2 (en) | 2017-10-09 | 2021-09-07 | Merck Sharp & Dohme Corp. | Substituted cyclobutylpyridine and cyclobutylpyrimidine compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors |
| EP3694502B1 (en) * | 2017-10-09 | 2023-08-02 | Merck Sharp & Dohme LLC | Novel substituted cyclobutylbenzene compounds as indoleamine 2,3-dioxygenase (ido) inhibitors |
| CN109836356B (zh) * | 2017-11-24 | 2022-03-08 | 沈阳化工研究院有限公司 | 一种芳甲醚衍生物及其应用 |
| US11447449B2 (en) | 2018-01-05 | 2022-09-20 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| SG11202009438UA (en) | 2018-04-18 | 2020-11-27 | Constellation Pharmaceuticals Inc | Modulators of methyl modifying enzymes, compositions and uses thereof |
| CN108715585A (zh) | 2018-04-23 | 2018-10-30 | 中国药科大学 | 苯基联三氮唑类mll1-wdr5蛋白-蛋白相互作用抑制剂 |
| CN112262143A (zh) | 2018-05-21 | 2021-01-22 | 星座制药公司 | 甲基修饰酶的调节剂、其组合物和用途 |
| WO2020018670A1 (en) | 2018-07-17 | 2020-01-23 | Board Of Regents, The University Of Texas System | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase |
| CN109734674B (zh) | 2019-02-26 | 2022-08-26 | 中国药科大学 | 苯胺类wdr5蛋白-蛋白相互作用抑制剂及其制法和用途 |
| PH12022550188A1 (en) | 2019-07-24 | 2022-11-21 | Constellation Pharmaceuticals Inc | Crystalline forms of 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-n-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide |
| WO2021102618A1 (en) * | 2019-11-25 | 2021-06-03 | InventisBio Co., Ltd. | Novel salts of indoleamine 2,3-dioxygenase inhibitors |
| CN111153846B (zh) * | 2020-01-17 | 2021-08-31 | 中国药科大学 | 吡咯类化合物、其制备方法和药物组合物与用途 |
| CN114369060B (zh) * | 2020-10-15 | 2023-11-03 | 杭州星鳌生物科技有限公司 | 吲哚胺2，3-双加氧酶抑制剂及其在制备抗肿瘤药物中的应用 |
| AU2022228701A1 (en) | 2021-03-05 | 2023-09-14 | Universität Basel | Compositions for the treatment of ebv associated diseases or conditions |
| EP4052705A1 (en) | 2021-03-05 | 2022-09-07 | Universität Basel Vizerektorat Forschung | Compositions for the treatment of ebv associated diseases or conditions |
| CN115594655B (zh) * | 2022-09-16 | 2023-08-15 | 桂林医学院 | 色酮肟类衍生物及其制备方法和应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH520667A (de) * | 1967-07-22 | 1972-03-31 | Merck Patent Gmbh | Verfahren zur Herstellung von Aminophenylessigsäuren |
| GR68102B (enExample) * | 1978-08-08 | 1981-10-30 | Fujisawa Pharmaceutical Co | |
| DE4107857A1 (de) * | 1991-03-12 | 1992-09-17 | Thomae Gmbh Dr K | Cyclische harnstoffderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| US5852192A (en) * | 1992-03-11 | 1998-12-22 | Dr. Karl Thomae Gmbh | Cyclic urea derivatives, pharmaceutical compositions containing these compounds and processes for preparing them |
| WO1997036862A1 (en) * | 1996-03-29 | 1997-10-09 | G.D. Searle & Co. | META-SUBSTITUTED PHENYLENE DERIVATIVES AND THEIR USE AS ALPHAvBETA3 INTEGRIN ANTAGONISTS OR INHIBITORS |
| EP1007037A4 (en) * | 1997-06-26 | 2004-10-06 | Lilly Co Eli | ANTITHROMBOTIC AGENTS |
| KR20050029209A (ko) | 2002-07-15 | 2005-03-24 | 미리어드 제네틱스, 인크. | 화합물, 조성물 및 이의 사용방법 |
| JP2004203791A (ja) * | 2002-12-25 | 2004-07-22 | Dai Ichi Seiyaku Co Ltd | 芳香族化合物 |
| JP2006519236A (ja) * | 2003-02-27 | 2006-08-24 | アボット・ラボラトリーズ | 複素環式キナーゼ阻害剤 |
| WO2004092146A2 (en) * | 2003-04-14 | 2004-10-28 | The Institutes For Pharmaceutical Discovery, Llc | N- (((((1,3-thiazol-2-yl) amino) carbonyl) phenyl) sulfonyl) phenylalanine derivatives and related compounds for the treatment of diabetes |
| GB0416508D0 (en) | 2004-07-23 | 2004-08-25 | Merck Sharp & Dohme | Therapeutic agents |
| WO2007123269A1 (ja) | 2006-04-19 | 2007-11-01 | Astellas Pharma Inc. | アゾールカルボキサミド誘導体 |
| WO2008156142A1 (ja) * | 2007-06-20 | 2008-12-24 | Mitsubishi Tanabe Pharma Corporation | 新規なマロン酸スルホンアミド誘導体およびその医薬用途 |
| EP2393811A1 (en) * | 2009-02-04 | 2011-12-14 | Pfizer Inc. | 4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-5(6h)-one derivatives |
| CA2758289A1 (en) | 2009-05-07 | 2010-11-11 | Gruenenthal Gmbh | Substituted aromatic carboxamide and urea derivatives as vanilloid receptor ligands |
| WO2010138901A1 (en) | 2009-05-29 | 2010-12-02 | Biogen Idec Ma Inc | Carboxylic acid-containing compounds, derivatives thereof, and related methods of use |
| EP2560488B1 (en) | 2010-04-23 | 2015-10-28 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
| JP2013526546A (ja) | 2010-05-13 | 2013-06-24 | アムジエン・インコーポレーテツド | Ｐｄｅ１０阻害剤としてのヘテロアリ−ルオキシヘテロシクリル化合物 |
| WO2012176123A1 (en) | 2011-06-22 | 2012-12-27 | Novartis Ag | 3 - imidazolyl- indoles for the treatment of proliferative diseases |
| JP2016512846A (ja) | 2013-03-13 | 2016-05-09 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | Ｒａｓ阻害剤およびその使用 |
| CN105324362B (zh) * | 2013-03-15 | 2017-05-24 | 百时美施贵宝公司 | Ido抑制剂 |
| MX2015011374A (es) | 2013-03-15 | 2016-01-15 | Squibb Bristol Myers Co | Inhibidores de indolamina 2,3-dioxigenasa (ido). |
| CA2917964A1 (en) * | 2013-07-11 | 2015-01-15 | Bristol-Myers Squibb Company | Ido inhibitors |
| WO2015007516A1 (en) * | 2013-07-15 | 2015-01-22 | Boehringer Ingelheim International Gmbh | Novel 5-substituted benzimidazolium compounds |
| BR112016018604A2 (pt) * | 2014-02-11 | 2017-08-08 | Bayer Pharma AG | Benzimidazol-2-aminas como inibidores de midh1 |
| JP6195684B2 (ja) | 2014-06-03 | 2017-09-13 | アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | ピラゾール化合物及びｔ型カルシウムチャンネルブロッカーとしてのそれらの使用 |
| JP6667537B2 (ja) * | 2015-01-12 | 2020-03-18 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 呼吸器系疾患の治療に有用な四置換及び五置換ベンズイミダゾリウム化合物 |
| US10689331B2 (en) * | 2015-06-26 | 2020-06-23 | Bristol-Myers Squibb Company | IDO inhibitors |
-
2017
- 2017-02-08 WO PCT/US2017/017063 patent/WO2017139414A1/en not_active Ceased
- 2017-02-08 CA CA3012133A patent/CA3012133A1/en active Pending
- 2017-02-08 CN CN201780009388.3A patent/CN109071423A/zh active Pending
- 2017-02-08 JP JP2018560739A patent/JP6979036B2/ja active Active
- 2017-02-08 BR BR112018015413A patent/BR112018015413A2/pt not_active Application Discontinuation
- 2017-02-08 EP EP17750724.1A patent/EP3414224B1/en active Active
- 2017-02-08 MX MX2018009633A patent/MX2018009633A/es unknown
- 2017-02-08 AU AU2017217536A patent/AU2017217536A1/en not_active Abandoned
- 2017-02-08 KR KR1020187025922A patent/KR102486298B1/ko active Active
- 2017-02-08 CN CN202111190675.3A patent/CN113896685B/zh active Active
- 2017-02-08 RU RU2018128334A patent/RU2018128334A/ru not_active Application Discontinuation
- 2017-02-08 US US16/073,679 patent/US10980807B2/en active Active
-
2021
- 2021-02-25 US US17/185,278 patent/US20220054486A1/en not_active Abandoned
-
2023
- 2023-02-09 US US18/166,789 patent/US11969425B2/en active Active